

Date: May 20, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Media Release – “Senores Pharmaceuticals acquires ANDA for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg from Wockhardt”

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of Media Release being issued by the Company on the captioned subject.

The same is also being uploaded on the website of the Company at www.senorespharma.com.

This is for information and records.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As mentioned above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

MEDIA RELEASE**Senores Pharmaceuticals acquires ANDA for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg from Wockhardt**

Atlanta, USA / Ahmedabad, India, May 20, 2025 – Senores Pharmaceuticals Limited (“SPL”), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (“SPI”), has signed agreement today to acquire the USFDA-approved Abbreviated New Drug Application (“ANDA”) for **Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg** from Wockhardt Limited (“Wockhardt”).

Enalapril is indicated as a treatment of **hypertension, heart failure, and asymptomatic left ventricular dysfunction**. The market size of **Enalapril Tablet** in the USA was ~USD **28.60** Mn (MAT December 2024)¹ as per IQVIA and ~USD **109.24** Mn (MAT March 2025)² as per the specialty data aggregator Symphony.

The acquisition will be funded through the Initial Public Offer (“IPO”) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited (together with its subsidiaries “**Senores**”) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies’ current portfolio includes 61 ANDA and 22 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 280 product registrations and 630 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“**API**”).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

¹ Source: IQVIA Database

² Source: Symphony

Safe Harbor Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact:

Company: Senores Pharmaceuticals Limited**CIN: L24290GJ2017PLC100263****Mr. Deval Shah**Email: investors@senorespharma.com

For updates and specific queries, please visit

www.senorespharma.com**Investor Relations: Strategic Growth Advisors****CIN: U74140MH2010PTC204285****Mr. Sagar Shroff / Mr. Tanay Shah**

M: +91 98205 19303 / +91 98333 91899

E-mail: sagar.shroff@sgapl.net /
tanay.shah@sgapl.net

For updates and specific queries, please visit

www.sgapl.net
